Erica Chimara

Erica Chimara

Auto-generated profile, based on publicly available information

Erica Chimara

Instituto Adolfo Lutz

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
LMLilian Regina Macelloni Marques
Lilian Regina Macelloni Marques
LFLucilaine Ferrazoli
Lucilaine Ferrazoli
ÉCÉrica Chimara
Érica Chimara
Objective: Pulmonary nontuberculous mycobacterial infections are caused by nontuberculous mycobacteria (NTM), the microbiological diagnosis of which involves the isolation and identification of the same species in at least two sputum samples, one BAL fluid sample, or one lung biopsy sample. The objective of the present study was to determine the frequency at which the various NTM species are identified among selected individuals and in potential cases of pulmonary nontuberculous mycobacterial infection. Methods: This was a retrospective analysis of the data on species isolated from respiratory specimens collected from 2,843 individuals between 2011 and 2014. Potential NTM infection cases were identified on the basis of the international microbiological criteria adopted in the state of São Paulo. Results: A total of 50 species were identified using the molecular method PCR-restriction enzyme analysis. Samples collected from 1,014 individuals were analyzed in relation to the microbiological criteria, and 448 (44.18%) had a presumptive diagnosis of pulmonary nontuberculous mycobacterial infection, the species identified most frequently being, in descending order, Mycobacterium kansasii, M. abscessus, M. intracellulare, M. avium, and M. szulgai. Conclusions: Although various NTM species were identified among the individuals studied, those presumptively identified most frequently on the basis of the microbiological criteria adopted in the state of São Paulo were the ones that are most commonly associated with pulmonary nontuberculous mycobacterial infection worldwide or in specific geographic regions.

29 October 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
RORosângela Siqueira Oliveira
Rosângela Siqueira Oliveira
ABAngela Pires Brandao
Angela Pires Brandao
FFFabiane Maria de Almeida Ferreira
Fabiane Maria de Almeida Ferreira
SCSonia Maria da Costa
Sonia Maria da Costa
VSVera Lucia Maria Silva
Vera Lucia Maria Silva
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
Drug-resistant tuberculosis (DR-TB) threatens global TB control. We investigated the prevalence and molecular characteristics of second-line drug resistance among rifampicin (RIF)- and/or isoniazid (INH)-resistant Mycobacterium tuberculosis complex (MTBC) isolates in São Paulo, Brazil, using the MTBDRsl v. 2.0 line-probe assay. MTBC isolates RIF- and/or INH-resistant by GenoType MTBDRplus or phenotypic testing (2019–2021) were subsequently tested by MTBDRsl for fluoroquinolone (FQ) and injectable drugs (capreomycin, amikacin, kanamycin) resistance. Isolates with inferred mutations underwent Sanger sequencing. Of 13,557 isolates, 728 (5.4%) were RIF- and/or INH-resistant (297 INH-R, 235 RIF-R, 196 MDR). Among them, 623 (85.6%) were tested by MTBDRsl; 582 (93.4%) showed no additional resistance, while 41 (6.6%) carried mutations. FQ resistance was detected in 38 isolates (92.7%), mostly in gyrA (n = 35). Three isolates with gyrB mutations were wild-type by sequencing. Two MDR isolates harbored the rrs a1401g mutation, and one also harbored gyrA D94G. Sequencing confirmed resistance in 38 of 41 isolates. Most MDR strains with second-line mutations (n = 32/33; 97%) were pre-XDR. Affected patients were predominantly male (68.4%), with pulmonary TB (92.1%), and unfavorable outcomes (39.5%). Second-line resistance prevalence was low overall, but FQ resistance was high among MDR isolates. Findings support integrating molecular and sequencing-based tools for accurate detection and management of DR-TB.

15 April 2025 in Journal of Medical Microbiology
Verified
Journal Article
Open access
CPCarolina Salgado Pedace
Carolina Salgado Pedace
RARobert D. Arbeit
Robert D. Arbeit
FSFernanda Cristina dos Santos Simeão
Fernanda Cristina dos Santos Simeão
JGJuliana Failde Gallo
Juliana Failde Gallo
ASAndréia Rodrigues de Souza
Andréia Rodrigues de Souza
ECErica Chimara
Erica Chimara
Introduction. Infections caused by Mycobacterium abscessus, an environmentally prevalent, rapidly growing mycobacteria, are increasingly frequent in developed countries. Objective. To analyse the drug susceptibility profiles of M. abscessus isolated in the state of São Paulo from 2008 to 2024. Methods. Of the 2,402 M. abscessus isolates identified during those 17 years, 558 (23.2%) met the American Thoracic Society’s microbiologic and clinical criteria for drug susceptibility testing (DST), which was performed for five agents – clarithromycin, amikacin, cefoxitin, ciprofloxacin, and doxycycline. Results. Clarithromycin showed a dramatic increase in resistance phenotype from ≤10% in the early period to 73–90% over the last 8 years. Over half those isolates demonstrated inducible resistance. Resistance to amikacin was found in fewer than 5% of isolates from 2016 to 2021. In 2022, that result increased to 13%, but for 2023 and 2024, it had fallen back to 2%. Over the past decade, cefoxitin DST has reported the majority of isolates as intermediate, a problematic result in M. abscessus group (MAG) infections, which typically require long-term treatment for successful outcomes. Since 2018, the annual susceptibility rate has been ≤18%, and in five of the 7 years, ≤7%. Ciprofloxacin was typically assessed as susceptible from 2009 to 2011, then decreased sharply to ≤20% over the next several years, and since 2018, the rate has been less than 5%. Through the entire study, doxycycline resistance has remained consistently high; in the years since 2018, ≤6% of isolates have been susceptible. Conclusion. This study demonstrates wide variation among MAG clinical isolates in the frequency of susceptibility, both across different agents and within individual agents over time. These results emphasize the importance of performing high-quality DST on MAG clinical isolates and suggest the need to consider revising the standard panel of drugs tested.

2 February 2022 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
AGAkemi Oshiro Guirelli
Akemi Oshiro Guirelli
TBThayná Rosa Bispo
Thayná Rosa Bispo
DCDaniela Rodrigues Colpas
Daniela Rodrigues Colpas
ICIvana Barros de Campos
Ivana Barros de Campos
ECErica Chimara
Erica Chimara
ACAndréia Moreira Dos Santos Carmo
Andréia Moreira Dos Santos Carmo

16 March 2023 in Journal of Medical Microbiology
Verified
Journal Article
Open access
CPCarolina Salgado Pedace
Carolina Salgado Pedace
MGMaria Gisele Gonçalves
Maria Gisele Gonçalves
ASAndréia Rodrigues Souza
Andréia Rodrigues Souza
FSFernanda Cristina dos Santos Simeão
Fernanda Cristina dos Santos Simeão
NCNatalia Fernandes Garcia de Carvalho
Natalia Fernandes Garcia de Carvalho
ECErica Chimara
Erica Chimara
Introduction. The M. abscessus molecular identification and its drug-resistance profile are important to choose the correct therapy. Aim. This work developed a multiplex real-time PCR (mqPCR) for detection of clarithromycin resistance genes for the Mycobacterium abscessus group. Methodology. Isolates received by Adolfo Lutz Institute from 2010 to 2012, identified by PCR restriction enzyme analysis of a fragment of the hsp65 gene (PRA-hsp65) as M. abscessus type 1 (n=135) and 2 (n=71) were used. Drug susceptibility test (DST) for CLA were performed with reading on days 3 and 14. Subespecies identification by hsp65 and rpoB genes sequencing and erm(41) and rrl genes for mutation detection and primer design were performed. erm(41) gene deletion was detected by conventional PCR. Primers and probes were designed for five detections: erm(41) gene full size and with deletion; erm(41) gene T28 and C28; rrl gene A2058. Results. In total, 191/206 (92.7 %) isolates were concordant by all methods and 13/206 (6.3 %) were concordant only between molecular methods. Two isolates (1.0 %) were discordant by mqPCR compared to rrl gene sequencing. The mqPCR obtained 204/206 (99.0 %) isolates in agreement with the gold standard, with sensitivity and specificity of 98 and 100 %, respectively, considering the gold standard method and 92 and 93 % regarding DST. Conclusion. The mqPCR developed by us proved to be an easy-to-apply tool, minimizing time, errors and contamination.

1 January 2025 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
RORosângela Siqueira de Oliveira
Rosângela Siqueira de Oliveira
ABAngela Pires Brandao
Angela Pires Brandao
FFFabiane Maria de Almeida Ferreira
Fabiane Maria de Almeida Ferreira
SCSonia Maria da Costa
Sonia Maria da Costa
VSVera Lucia Maria da Silva
Vera Lucia Maria da Silva
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
Background: In this study, we aimed to describe the mutations associated with first-line drug resistance in Mycobacterium tuberculosis complex (MTBC) isolates from São Paulo, Brazil, between 2019 and 2021. Methods: Mutations in the coding regions of rpoB and katG genes and in the promoter region of the inhA gene in MTBC clinical isolates were detected using the GenoType MTBDRplus assay (LPA). All mutations inferred by LPA were sequenced. Results: Of the 13,489 MTBC isolates with valid LPA results, 657 (4.9%) harbored mutations. The overall prevalence rates of rifampicin-resistant (RIF-R) tuberculosis (TB), isoniazid-resistant (INH-R) TB, and multidrug-resistant (MDR) TB were 1.5, 2.0, and 1.2%, respectively. A significant proportion of RIF-R isolates presented inferred rpoB mutations (89.1%), most of which were the borderline H445N mutation. The inhA promoter C-15T mutation was predominant among the INH-R isolates (52.8%). Most MDR isolates presented rpoB S450L + katG S315T1 mutations. Gene sequencing identified mutations not included in the catalogue of mutations published by the World Health Organization. Phenotypic drug susceptibility testing on isolates with inferred rpoB mutations revealed that the 0.5 µg/mL critical concentration of RIF failed to detect most borderline mutations when using the BACTEC MGIT 960 system. Conclusions: These findings emphasize the need for continuous surveillance and the integration of molecular and phenotypic methods to ensure an accurate detection and management of drug-resistant TB in high-burden settings.